Search

Displaying results 1531 - 1540 of 7479 in total
  1. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

  2. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  3. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal

  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  6. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    , the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or hepatic decompensation) due

  7. Drug

    Cetrorelix

    go.drugbank.com/drugs/DB00050
    ApprovedInvestigational

    Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). … When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released.

  8. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to ...

  9. Target

    Beta-ketoacyl-[acyl-carrier-protein] synthase III

    go.drugbank.com/bio_entities/BE0003868
    TargetEnterococcus faecalis (strain ATCC 700802 / V583)

    Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role...

    Synonyms: KAS III
  10. Drug

    AS-8112

    go.drugbank.com/drugs/DB09207
    Experimental

    AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.

    Categories: Dopamine D2 Receptor Antagonists